Literature DB >> 6332863

Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults.

M L Lepow, J S Samuelson, L K Gordon.   

Abstract

Sixty-one adults received either Haemophilus influenzae type b capsular polyribosephosphate (PRP) vaccine or H. influenzae type b polysaccharide-diphtheria toxoid conjugate (PRP-D) vaccine in two doses, one month apart. Both vaccines were well tolerated with no fever or systemic reactions. There were no significant local reactions. Mild local tenderness was reported by about half of the subjects in both groups. There was no observed effect of the vaccines on hematologic parameters, including reticulocyte and platelet counts, evaluated before immunization, one month after the first dose, and seven to 10 days after the second dose. A single dose of PRP-D induced levels of IgG antibody to PRP three times that observed with PRP alone one month after the first inoculation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332863     DOI: 10.1093/infdis/150.3.402

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Applications of polysaccharides. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1986-04       Impact factor: 2.926

2.  Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine.

Authors:  K L Cates; K H Marsh; D M Granoff
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

Review 3.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

4.  Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers.

Authors:  Gilda Toraño; Maria E Toledo; Alberto Baly; Violeta Fernandez-Santana; Francisco Rodriguez; Yunia Alvarez; Teresita Serrano; Alexis Musachio; Ibis Hernandez; Eugenio Hardy; Arlene Rodríguez; Hector Hernandez; Aristides Aguilar; Raydel Sánchez; Manuel Diaz; Verena Muzio; Jorgelina Dfana; Maria C Rodríguez; Lazaro Heynngnezz; Vicente Verez-Bencomo
Journal:  Clin Vaccine Immunol       Date:  2006-09

5.  Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.

Authors:  C C Peeters; D Evenberg; P Hoogerhout; H Käyhty; L Saarinen; C A van Boeckel; G A van der Marel; J H van Boom; J T Poolman
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

6.  Chemical evidence for covalent linkages of a semi-synthetic glycoconjugate vaccine for Haemophilus influenzae type B disease.

Authors:  R C Seid; R A Boykins; D F Liu; K W Kimbrough; C L Hsieh; R Eby
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

7.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

Review 9.  Safety of routine childhood vaccinations. An epidemiological review.

Authors:  R T Chen; G Mootrey; F DeStefano
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.930

10.  Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold.

Authors:  Payton A-B Weidenbacher; Frances P Rodriguez-Rivera; Mrinmoy Sanyal; Joshua A Visser; Jonathan Do; Carolyn R Bertozzi; Peter S Kim
Journal:  ACS Chem Biol       Date:  2022-04-12       Impact factor: 4.634

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.